Nasopharyngeal angiotensin converting enzyme 2 (ACE2) expression as a risk-factor for SARS-CoV-2 transmission in concurrent hospital associated outbreaks.

"data availability the datasets generated and/or analysed during the current study are available in the "figshare" repository 10 6084/m9 figshare 24158637 v1. data availability the datasets generated and/or analysed during the current study are available in the "figshare"

"Declarations Ethics approval and consent to participateEthical approval for the study was sought from the University of British Columbia Human Ethics Board (#H20-01110) which was harmonized with the Fraser Health Authority. Written informed consent was not required and waived by the University of British Columbia Human Ethics Board. All data was de-identified prior to analysis and the results were not linked back to any identifying records. This study was deemed as minimal risk to the participants involved. To ensure privacy the site of the outbreak series will not be disclosed. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was funded by the Canadian Institutes of Health Research (#434951) and Genome British Columbia (COV-55)."